Johnson & Johnson (NYSE:JNJ) Releases FY 2026 Earnings Guidance

Johnson & Johnson (NYSE:JNJ) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 11.050-11.150 for the period, compared to the consensus estimate of 11.100. The company issued revenue guidance of $101.0 billion-$101.4 billion, compared to the consensus revenue estimate of $101.3 billion.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $253.49 on Thursday. Johnson & Johnson has a 12-month low of $184.66 and a 12-month high of $281.07. The business’s fifty day simple moving average is $265.80 and its 200-day simple moving average is $249.47. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a market cap of $610.89 billion, a PE ratio of 38.41, a PEG ratio of 2.54 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the previous year, the business earned $2.80 EPS. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts expect that Johnson & Johnson will post 11.10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s payout ratio is currently 62.11%.

Analysts Set New Price Targets

A number of analysts have commented on the company. Royal Bank Of Canada lowered their price target on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday. Scotiabank reiterated an “outperform” rating and issued a $305.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. Citigroup upped their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a report on Monday, October 5th. Weiss Ratings upgraded Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Finally, HSBC lifted their price target on Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $273.61.

Insiders Place Their Bets

In other news, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 87,569 shares of company stock worth $23,064,544. Company insiders own 0.16% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported adjusted third-quarter EPS of $2.59, above the $2.53 consensus estimate, while revenue increased 5.9% year over year to approximately $25.4 billion. Innovative Medicine was the main growth driver, with pharmaceutical sales benefiting from oncology products, TREMFYA and newer medicines. Johnson & Johnson Q3 Earnings Surpass Estimates
• Positive Sentiment: Management raised its full-year 2026 outlook to $101.0 billion-$101.4 billion in revenue and adjusted EPS of $11.05-$11.15. The company also declared a quarterly dividend of $1.34 per share, supporting JNJ’s income-investment appeal. Johnson & Johnson raises 2026 guidance as quarterly sales climb
• Positive Sentiment: Royal Bank of Canada maintained an “outperform” rating, although it lowered its price target from $290 to $280. Management is also considering a mid-2027 spinoff of its DePuy Synthes orthopedics business, which could sharpen the focus of the remaining MedTech operations. Johnson & Johnson MedTech sets mid-2027 target for ortho spinoff
• Neutral Sentiment: Analysts expect JNJ’s December 8 enterprise review to provide more detail on portfolio strategy, MedTech investments and the potential orthopedics separation. The review could clarify the company’s longer-term growth plan. Johnson & Johnson’s Enterprise Review Expected to Sharpen Outlook
• Negative Sentiment: MedTech sales missed Wall Street expectations, with weakness in cardiovascular and surgery businesses, particularly outside the United States. China pricing pressure, European budget reductions and Middle East-related disruptions added to concerns about the segment’s near-term growth.
• Negative Sentiment: Reported profit was sharply reduced by special charges tied to the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration. Analysts subsequently trimmed several earnings estimates and price targets, while management warned that new drug deals could dilute 2027 earnings. Johnson & Johnson falls after quarterly report despite higher 2026 outlook

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.